Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukaemia (CLL). Ulocuplumab exhibits antitumor activity in established tumours including acute myeloid leukaemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.
| Name | Citation | CXCR1 | CXCR2 | CXCR4 | Others |
|---|---|---|---|---|---|
| WZ811 | 20 | ||||
| SB 225002 | 91 | ||||
| Reparixin (Repertaxin) | 24 | CXCL8 | |||
| AMD3465 hexahydrobromide | 1 |
| Description |
Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukaemia (CLL). Ulocuplumab exhibits antitumor activity in established tumours including acute myeloid leukaemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.
|
|---|
| CAS No. | 1375830-34-4 |
|---|---|
| Molecular Weight | 144.84 kDa |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.